APMONIA THERAPEUTICS

Apmonia Therapeutics is a biotech company committed to develop therapeutic strategies towards multiple types of cancer... Apmonia Therapeutics was founded in 2019 as spin-off of CNRS and Reims university (UMR 7369 MEDyC). Executive team now gathers together members with decades of experience in leading research institutes and biotech industry... Apmonia Therapeutics' lead program (AP-01) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet medical needs. Meanwhile, other promising programs are on track targeting extracellular matrix components.

Primary location: Reims France